✦ LIBER ✦
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
✍ Scribed by R. Gomis; D. R. Owens; M.-R. Taskinen; S. Del Prato; S. Patel; A. Pivovarova; A. Schlosser; H.-J. Woerle
- Book ID
- 114826077
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 189 KB
- Volume
- 66
- Category
- Article
- ISSN
- 1368-5031
No coin nor oath required. For personal study only.